- Previous Close
17.56 - Open
17.39 - Bid 17.54 x --
- Ask 17.55 x --
- Day's Range
17.27 - 17.62 - 52 Week Range
11.92 - 24.11 - Volume
9,687,212 - Avg. Volume
12,429,226 - Market Cap (intraday)
13.285B - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
20.41 - EPS (TTM)
0.86 - Earnings Date --
- Forward Dividend & Yield 0.20 (1.14%)
- Ex-Dividend Date Jul 31, 2024
- 1y Target Est
--
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotic, immunosuppressive, and others. The company provides medicine and food, skin care, oral care, private care, and time-honored food series; and other products, such as oral medication and injections. It markets artemisinin antimalarials, generic drugs, and medical apparatus. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. The company was founded in 1951 and is based in Kunming, the People's Republic of China.
www.kpc.com.cn5,275
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 600422.SS
View MorePerformance Overview: 600422.SS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600422.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600422.SS
View MoreValuation Measures
Market Cap
13.28B
Enterprise Value
11.38B
Trailing P/E
20.41
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.57
Price/Book (mrq)
2.53
Enterprise Value/Revenue
1.35
Enterprise Value/EBITDA
9.84
Financial Highlights
Profitability and Income Statement
Profit Margin
7.71%
Return on Assets (ttm)
4.02%
Return on Equity (ttm)
10.22%
Revenue (ttm)
8.4B
Net Income Avi to Common (ttm)
648.08M
Diluted EPS (ttm)
0.86
Balance Sheet and Cash Flow
Total Cash (mrq)
2.74B
Total Debt/Equity (mrq)
12.35%
Levered Free Cash Flow (ttm)
2.48B